BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TARA-002 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TARA-002\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05871970-10925@assetmemo.bio
DTSTAMP:20261121T005841Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TARA-002: Phase 2 readout est. (NCT05871970)
DESCRIPTION:TARA-002\, phase 2.\nStudy: Safety and Efficacy Study of Intrac
 ystic TARA-002 for the Treatment of Lymphatic Malformations in Participant
 s 6 Months to Less Than 18 Years of Age\nEstimated primary completion: Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0587
 1970
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07480356-10925@assetmemo.bio
DTSTAMP:20261121T005841Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:TARA-002: Phase 3 readout est. (NCT07480356)
DESCRIPTION:TARA-002\, phase 3\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Efficacy and Safety of Intravesical TARA-002 Compared With Investigator'
 s Choice of Intravesical Chemotherapy in Participants With BCG-naïve High
 -grade Non-muscle Invasive Bladder Cancer\nEstimated primary completion: A
 pril 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tara-002#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07480
 356
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951179-10925@assetmemo.bio
DTSTAMP:20261121T005841Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:TARA-002: Phase 2 readout est. (NCT05951179)
DESCRIPTION:TARA-002\, phase 2\, Non-Muscle Invasive Bladder Cancer.\nStudy
 : Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Ad
 ults With High-grade Non-muscle Invasive Bladder Cancer\nEstimated primary
  completion: October 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tara-002#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05951179
URL:https://assetmemo.bio/drug/tara-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
